Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Sherlock Biosciences Inc.
Headquarters: Cambridge, MA, United States of America
Website: N/A
Year Founded: 2019
Status: Acquired
BioCentury | Oct 23, 2024
Discovery & Translation
Science Spotlight: Novo’s glucose-sensing insulin, two bacterial immunotherapies, and more
BioCentury’s roundup of translational innovations
BioCentury | Jun 14, 2024
Finance
Venture Report: Clinical plays Alzheon, Bright Peak raise growth capital
Plus: Early-stage financings for InduPro, Syntis and Moleculent; J.P. Morgan closes its life sciences vehicle; and a new fund for spinal injury
BioCentury | May 17, 2023
Discovery & Translation
Acidifying lysosomes to treat NAFLD; Sherlock’s nucleic acid assay and more
BioCentury’s roundup of translational news
BioCentury | Apr 13, 2023
Management Tracks
SVB’s Sabow to lead HSBC tech, healthcare business
Plus: Century revamps C-suite amid CEO departure and updates from Bausch + Lomb, Gennao, Celares, Sherlock, Viridian and more
BioCentury | Apr 11, 2023
Discovery & Translation
Inhalable nanoparticles for lung mRNA delivery and gene editing; nanobody secretion by E. coli in the gut and more
BioCentury’s roundup of translational news
BioCentury | Feb 23, 2023
Deals
Feb. 22 Quick Takes: Moderna adds third gene editing partnership
Plus: Graphite terminates sickle cell program, FDA reviewing Pfizer’s bispecific, and updates from Zai Lab, Sherlock, Abivax and more
BioCentury | Feb 2, 2023
Regulation
Feb. 1 Quick Takes: FDA approves GSK’s daprodustat
Plus: Patient Square caps first fund at $3.9B, and updates from Verily-Otsuka Novartis, Evelo, Sherlock-Sense, Recurv and more
BioCentury | Jul 14, 2022
Management Tracks
New CEO at Deerfield-backed Apertura
Plus 10x Genomics hires Wilbur to head commercial, and updates from Immune-Onc, PathAI, Sherlock and more
BioCentury | Apr 8, 2022
Management Tracks
Ancestry’s Georgiadis joins Flagship as CEO-partner
Plus Melton rejoining Sanna at Vertex and updates from CARsgen, Third Harmonic and more
BioCentury | Mar 9, 2022
Finance
March 8 Quick Takes: Blackstone backs DNAnexus with $200M
Plus Sherlock raises $80M and updates from WuXi AppTec, Mustang, UroGen and more
Items per page:
1 - 10 of 46